【作者】 胡卫; 汤绍辉;
【Author】 HU Wei,TANG Shao-hui 1.Hospital of Wuhan University,Wuhan,China,430072; 2.Jinan University Qverseas Hospital
【机构】 武汉大学医院; 暨南大学华侨医院;
【摘要】 目的系统评价L-鸟氨酸-L-门冬氨酸(L-ornithine-L-aspartate,LOLA)治疗肝性脑病(hepaticencephalopathy,HE)的疗效和不良反应。方法计算机检索PubMed、EMbase、Web of Science、e CochraneCentral Register of Controlled Trials(CENTRAL)、CNKI、VIP、WanFang Data(检索时间截至2011年11月30日),纳入LOLA治疗肝性脑病的随机对照试验(RCT),由两位评价员独立评价纳入研究的质量、进行资料提取和交叉核对后,采用RevMan 5.0软件进行Meta分析。结果纳入6个RCT,C型HE患者432例,A型HE患者185例。Meta分析结果显示:与安慰剂相比,LOLA能明显降低C型HE患者的血氨水平[WMD=16.60,95%CI(8.34,24.85,P<0.000 1],改善数字连接试验(NCT-A)反应时间[WMD=9.6,95%CI(5.26,13.93),P<0.000 1],有效提高HE临床缓解率[RR=1.36,95%CI(... 更多还原
【Abstract】 Objective To evaluate the efficacy and safety of L-ornithine-L-aspartate(LOLA) in the treatment of hepatic encephalopathy(HE).Methods Such databases as PubMed,EMbase,Web of Science,CENTRAL,Chinese Journals Full-text Database,CBM and WanFang Data were searched from the date of their establishment to November 30,2011 to collect the randomized controlled trials(RCTs) on LOLA in treating HE.The quality of included studies was evaluated by two reviewers independently,data were extracted and cross-che... 更多还原 【关键词】 L-鸟氨酸-L-门冬氨酸; 肝性脑病; 系统评价; Meta分析; 随机对照试验; 【Key words】 L-ornithine-L-aspartate; Hepatic encephalopathy; Systematic review; Meta——analysis; Randomized controlled trial;
【分类号】R747.9
中华医学之家:http://www.xinxi85.com
投稿信箱:zhyxzj85@163.com
联系电话:029--13309215487 主编QQ:693891972 |